Table 1.
Association between KIF23 expression levels and clinical characteristics in the TCGA-GC cohorts.
| Characteristic | Low expression of KIF23 (n=187) | High expression of KIF23 (n=188) | p-value |
|---|---|---|---|
| Pathologic T stage, n (%) | 0.756 | ||
| T1 | 10 (2.7%) | 9 (2.5%) | |
| T2 | 44 (12%) | 36 (9.8%) | |
| T3 | 84 (22.9%) | 84 (22.9%) | |
| T4 | 47 (12.8%) | 53 (14.4%) | |
| Pathologic N stage, n (%) | 0.904 | ||
| N0 | 58 (16.2%) | 53 (14.8%) | |
| N1 | 48 (13.4%) | 49 (13.7%) | |
| N2 | 35 (9.8%) | 40 (11.2%) | |
| N3 | 37 (10.4%) | 37 (10.4%) | |
| Pathologic M stage, n (%) | 0.626 | ||
| M0 | 161 (45.4%) | 169 (47.6%) | |
| M1 | 14 (3.9%) | 11 (3.1%) | |
| Pathologic stage, n (%) | 0.356 | ||
| Stage I | 28 (8%) | 25 (7.1%) | |
| Stage II | 59 (16.8%) | 52 (14.8%) | |
| Stage III | 75 (21.3%) | 75 (21.3%) | |
| Stage IV | 14 (4%) | 24 (6.8%) | |
| Primary therapy outcome, n (%) | 0.635 | ||
| PD | 30 (9.5%) | 35 (11%) | |
| SD | 9 (2.8%) | 8 (2.5%) | |
| PR | 1 (0.3%) | 3 (0.9%) | |
| CR | 120 (37.9%) | 111 (35%) | |
| Gender, n (%) | 0.776 | ||
| Female | 65 (17.3%) | 69 (18.4%) | |
| Male | 122 (32.5%) | 119 (31.7%) | |
| Age, n (%) | 0.004 | ||
| <=65 | 96 (25.9%) | 68 (18.3%) | |
| >65 | 89 (24%) | 118 (31.8%) | |
| Histological type, n (%) | 0.006 | ||
| Diffuse Type | 42 (11.2%) | 21 (5.6%) | |
| Mucinous Type | 13 (3.5%) | 6 (1.6%) | |
| Not Otherwise Specified | 100 (26.7%) | 107 (28.6%) | |
| Papillary Type | 2 (0.5%) | 3 (0.8%) | |
| Signet Ring Type | 6 (1.6%) | 5 (1.3%) | |
| Tubular Type | 24 (6.4%) | 45 (12%) | |
| Residual tumor, n (%) | 0.777 | ||
| R0 | 154 (46.8%) | 144 (43.8%) | |
| R1 | 7 (2.1%) | 8 (2.4%) | |
| R2 | 7 (2.1%) | 9 (2.7%) | |
| H pylori infection, n (%) | 0.030 | ||
| No | 61 (37.4%) | 84 (51.5%) | |
| Yes | 13 (8%) | 5 (3.1%) | |
| Histologic grade, n (%) | 0.129 | ||
| G1 | 5 (1.4%) | 5 (1.4%) | |
| G2 | 59 (16.1%) | 78 (21.3%) | |
| G3 | 118 (32.2%) | 101 (27.6%) |